respectively, p=0.034). We used the ratio between the pelvic EEC and HC to express a proportion score (PS) for CPD. The PS was signifi- cantly smaller in ID and CS-CPD, in comparison to NVD, in all pelvic levels: inlet (1.080.1 and 1.090.1 VS 1.150.08, p=0.006); mid (0.920.09 and 0.970.1 VS 1.030.08, p=0.0003); and outlet (0.770.04 and 0.810.07 VS 0.840.08 p=0.011). ROC analysis showed that a mid pelvis PS of 1 had a 68% sensitivity, 58% specificity and a positive predictive value of 89% for CS-CPD. CONCLUSION: Low proportion score of maternal pelvic parameters and neonate head circumference, is highly correlated with ID and CS- CPD. 115 Placental abruption as a marker for long term cardiovascular mortality: a follow up period of more than a decade Gali Pariente 1 , Ilana Shoham-Vardi 2 , Roy Kessous 1 , Eyal Sheiner 1 1 Soroka University Medical Center, Department of Obstetrics and Gynecology, Beer sheva, Israel, 2 Soroka University Medical Center, Faculty of Health Sciences, Beer sheva, Israel OBJECTIVE: To investigate the risk for subsequent cardiovascular events in women having placental abruption, during a follow-up pe- riod of more than 10 years. STUDY DESIGN: A population-based study comparing consecutive pregnancies of women with and without placental abruption was con- ducted. Deliveries occurred during the years 1988-1999 and had a follow up until the year 2010. Associations between placental abrup- tion and maternal long-term cardiovascular hospitalizations, mor- bidity and mortality were investigated. Multivariable analysis was used to control for confounders. RESULTS: During the study period, there were 47,909 deliveries who met the inclusion criteria, of these 1.4% (n=653) occurred in patients with placental abruption. No significant differences were noted re- garding subsequent long term hospitalizations due to cardiovascular causes during at least a decade of follow-up (OR= 1.2, 95% CI 0.8-1.8, P=0.314), as well as regarding invasive procedures (OR=1.5 95% CI 0.7-3.3, P=0.312; table). However, placental abruption was noted as a risk factor for long term cardiovascular mortality (OR= 6.6, 95% CI 2.3-18.4, P=0.004). The case fatality rate for placental abruption was 13.0% vs. 2.5% in the comparison group. ( P0.001). In a multivar- iate logistic regression model, after controlling for confounders such as ethnicity and maternal age, placental abruption was noted as an independent risk factor for maternal long-term cardiovascular mor- tality (adjusted OR= 4.5; 95% CI-1.1-19.1, P = 0.041). CONCLUSION: Placental abruption is a significant risk factor for long- term cardiovascular mortality in a follow-up period of more than a decade. 116 Giving birth to a small for gestational age infant is a risk factor for long-term maternal cardiovascular morbidity Gali Pariente 1 , Roy Kessous 1 , Ilana Shoham-Vardi 2 , Eyal Sheiner 1 1 Soroka University Medical Center, Ben-Gurion University of the Negev, Department of Obstetrics and Gynecology, Beer-Sheva, Israel, 2 Soroka University Medical Center, Ben-Gurion University of the Negev, Faculty of Health Sciences, Beer-Sheva, Israel OBJECTIVE: To investigate whether women with a prior occurrence of small-for-gestational-age (SGA) are at an increased risk for subse- quent long term maternal cardiovascular morbidity. STUDY DESIGN: A population-based study comparing consecutive pregnancies of women with and without a previous delivery of a SGA neonate was conducted. Deliveries occurred during the years 1988- 1999, with a follow-up period until 2010. Incidence of long-term car- diovascular morbidity was compared between women with SGA ne- onate and women who gave birth at the same period to an appropriate for gestational age neonate. Logistic regression was conducted to ob- tain adjusted odds ratios (AOR) and 95 % confidence intervals (CI) for the association between SGA and subsequent cardiovascular morbidity. RESULTS: During the study period 47612 deliveries met the inclusion criteria; 9.3% (n=4411) occurred in patients with a prior occurrence of SGA. Women with a prior occurrence of SGA had higher rates of long term complex cardiovascular events such as congestive heart fail- ure, cardiac arrest etc. (OR=2.3; 95% CI 1.3-4.4, P=0.006) and long term cardiovascular mortality (OR= 3.4; 95% CI 1.5-7.6, P=0.006; table). Using a multivariable logistic regression model, controlling for confounders such as maternal age and ethnicity, having delivered a SGA neonate was noted as an independent risk factor for long-term maternal cardiovascular hospitalizations (AOR= 1.4; 95% CI-1.1- 1.6, P  0.001). CONCLUSION: Delivery of a previous SGA infant is an important pre- dictor of long-term maternal cardiovascular morbidity during a fol- low-up period of more than a decade. 117 Misoprostol for treatment of intrauterine fetal death at 14-28 weeks of pregnancy Hillary Bracken 1 , Nguyen thi Nhu Ngoc 2 , Erika Banks 3 , Paul Blumenthal 4 , Richard Derman 5 , Ashlesha Patel 6 , Marji Gold 7 , Beverly Winikoff 8 1 Gynuity Health Projects, New York, NY, 2 Center for Research and Consultancy in Reproductive Health (CRCRH), Ho Chi Minh City, Viet Nam, 3 Albert Einstein College of Medicine, Department of Obstetrics and Gynecology, New York, NY, 4 Stanford University, Family Planning Services and Research, Palo Alto, CA, 5 Christiana Care Hospital, Department of Obstetrics and Gynecology, Newark, DE, 6 JH Stroger Jr. Hospital of Cook County, Department of Obstetrics and Gynecology, Chicago, IL, 7 Albert Einstein College of Medicine, Department of Family Medicine, New York, NY, 8 Gynuity Health Projects, New York, NY OBJECTIVE: To systematically assess whether misoprostol has high safety and effectiveness for the treatment of intrauterine fetal death at 14-28 weeks of pregnancy and to help establish the best dose of miso- prostol for this purpose. STUDY DESIGN: This double-blind trial randomized 153 women, 14-28 weeks gestation, into two groups. Women received either 100mcg buccal misoprostol (Group 1) or 200 mcg buccal misoprostol (Group 2) every 6h for a maximum of 8 doses. The primary outcome was successful evacuation within 48h. RESULTS: The 200mcg dose was significantly more effective than the 100 mcg dose at evacuating the uterus within 48h (Group 1: 66.7%; Group 2: 84.2% (RR 0.79 (95%CI: 0.65-0.95). The mean time to evac- uation was significantly shorter in Group 2 (18.9h +11.9h) than Group 1 (24.0 +12.4h) (p=0.03). The side effect profile was similar in the two groups. Few women reported nausea (Group 1: 19%; Group 2: 24%), vomiting (Group 1: 10%; Group 2: 16%), chills (Group 1: 24%; Group 2:21%) or headache (Group 1: 16%; Group 2: 21%). However, significantly more women in the 200mcg group reported diarrhea Subsequent cardiovascular events in women having placental abruption Long term cardiovascular morbidity and mortality in patients with and without a prior occurrence of SGA Poster Session I Clinical Obstetrics, Epidemiology, Fetus, Medical-Surgical Complications, Neonatology, Physiology/Endocrinology, Prematurity www.AJOG.org S62 American Journal of Obstetrics & Gynecology Supplement to JANUARY 2013